Laurent Bezin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Laurent Bezin has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Béatrice Georges
Lyon 1 Universite, CNRS UMR5292, Inserm U1028, Centre de Recherche en Neurosciences de Lyon, F-69500 Bron, France
13 shared publications- Sylvain Rheims
Department of Functional Neurology and Epileptology Hospices Civils de Lyon and Lyon 1 University Lyon France
11 shared publications Jacques Bodennec
CNRS UMR5292, Inserm U1028, TIGER Team, Université Claude Bernard Lyon 1, Centre de Recherche en Neurosciences de Lyon, Bron, France
8 shared publicationsAnne Morales
CRNL, Lyon Neuroscience Research Center, Inserm U1028, CNRS UMR5292, Lyon 1 University, Bron, France
7 shared publicationsMichaël Ogier
French Armed Forces Biomedical Research Institute (IRBA), Brétigny-sur-Orge, France
6 shared publications- Wanda Grabon
Université Claude Bernard Lyon 1, CNRS UMR5292, Inserm U1028, Centre de Recherche en Neurosciences de Lyon, TIGER Team, F-69500 Bron, France
6 shared publications
Latest Publications
- Open Access
CB2 activation during epileptogenesis recruits immunomodulatory monocytes and mitigates cognitive, affective and seizure outcomes
Temporal lobe epilepsy (TLE) is frequently associated with severe cognitive impairment and psychiatric comorbidities that are highly disabling and not targeted by anti-seizure medications, highlighting the need for therapies that target epileptogenesis rather than merely suppress seizures. Despite strong evidence implicating neuroinflammation in this process, anti-inflammatory approaches have not yielded such therapies yet. Infiltrating peripheral monocytes are widely viewed as detrimental amplifiers of post–status epilepticus (SE) inflammation, although emerging data suggest context-dependent protective roles. The cannabinoid receptor type 2 (CB2), highly expressed in myeloid cells, represents a potential immunomodulatory target linking leukocyte recruitment and inflammatory polarization. Using a juvenile rat model of TLE, we characterized hippocampal neuroinflammation and CB2 expression during epileptogenesis and evaluated the effects of transient CB2 activation with the selective agonist GP1a. SE induced a rapid but transient inflammatory response and robust recruitment of peripheral monocytes that persisted as anti-inflammatory monocyte-derived macrophages. CB2 activation did not suppress early cytokine induction but selectively enhanced recruitment of anti-inflammatory monocytes and modestly increased anti-inflammatory signaling. Importantly, transient CB2 stimulation preserved synaptic plasticity, improved cognitive performance, reduced anxiety-like behavior, and delayed seizure onset. These findings identify CB2-dependent modulation of peripheral myeloid cells as a potential disease-modifying axis in TLE.
Open AccessCB2 activation during epileptogenesis recruits immunomodulatory monocytes and mitigates cognitive, affective and seizure outcomes
Temporal lobe epilepsy (TLE) is frequently associated with severe cognitive impairment and psychiatric comorbidities that are highly disabling and not targeted by anti-seizure medications, highlighting the need for therapies that target epileptogenesis rather than merely suppress seizures. Despite strong evidence implicating neuroinflammation in this process, anti-inflammatory approaches have not yielded such therapies yet. Infiltrating peripheral monocytes are widely viewed as detrimental amplifiers of post–status epilepticus (SE) inflammation, although emerging data suggest context-dependent protective roles. The cannabinoid receptor type 2 (CB2), highly expressed in myeloid cells, represents a potential immunomodulatory target linking leukocyte recruitment and inflammatory polarization. Using a juvenile rat model of TLE, we characterized hippocampal neuroinflammation and CB2 expression during epileptogenesis and evaluated the effects of transient CB2 activation with the selective agonist GP1a. SE induced a rapid but transient inflammatory response and robust recruitment of peripheral monocytes that persisted as anti-inflammatory monocyte-derived macrophages. CB2 activation did not suppress early cytokine induction but selectively enhanced recruitment of anti-inflammatory monocytes and modestly increased anti-inflammatory signaling. Importantly, transient CB2 stimulation preserved synaptic plasticity, improved cognitive performance, reduced anxiety-like behavior, and delayed seizure onset. These findings identify CB2-dependent modulation of peripheral myeloid cells as a potential disease-modifying axis in TLE.
- Open Access
- 9 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1695856
Brain-infiltrated monocyte macrophages in a rat model of temporal lobe epilepsy: revisiting the pro-inflammatory paradigm
Neuroinflammation is central to temporal lobe epilepsy, yet the specific role of myeloid cells remains unclear. In status epilepticus (SE) models, circulating monocytes infiltrate the brain, although distinguishing them from microglia is challenging. Using a rat model, we traced infiltrating monocytes post-SE to investigate their persistence, phenotypic evolution during epileptogenesis and contribution to neuroinflammation. By tracking phagocytosed fluorescent nanoparticles and performing CD68 immunohistochemistry, we confirmed that monocytes entered the brain in significant numbers 24 hours post-SE, after the inflammatory peak occurred (7 hours). Their long-term presence and evolution into monocyte-macrophages (mo-mΦs) up to 7 weeks were monitored histologically using CD68. Distinct inflammatory profiles were further characterized after cell enrichment and fluorescence-activated cell sorting (FACS) distinguishing monocytes/mo-mΦs (CD11b + CD45 hi CD11a hi ) from microglia (CD11b + CD45 lo CD11a lo ). Microglia were the main drivers of the early pro-inflammatory response, with TNFα transcript levels nearly 14-fold higher in microglia than in monocytes 24h post-SE. In contrast, 24h post-SE, infiltrating monocytes transiently displayed an anti-inflammatory and neuroprotective phenotype, being the main source of IL-10, showing ~4-fold higher CD206, and expressing Arg1 absent in microglia. Tracked up to 7 weeks, these cells progressively adopted a microglia-like phenotype, contributed to the microglial scar and, although their expression of pro-inflammatory markers resembled nonactivated microglia, we hypothesize that their persistent presence might fuel the low-grade inflammation typical of chronic epilepsy. Importantly, since infiltrating monocytes initially engage in a transient anti-inflammatory response, strategies aiming to sustain or enhance this protective role in the context of epileptogenesis and epilepsy may open promising avenues for therapeutic intervention.
- 9 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1695856
Open AccessBrain-infiltrated monocyte macrophages in a rat model of temporal lobe epilepsy: revisiting the pro-inflammatory paradigm
Neuroinflammation is central to temporal lobe epilepsy, yet the specific role of myeloid cells remains unclear. In status epilepticus (SE) models, circulating monocytes infiltrate the brain, although distinguishing them from microglia is challenging. Using a rat model, we traced infiltrating monocytes post-SE to investigate their persistence, phenotypic evolution during epileptogenesis and contribution to neuroinflammation. By tracking phagocytosed fluorescent nanoparticles and performing CD68 immunohistochemistry, we confirmed that monocytes entered the brain in significant numbers 24 hours post-SE, after the inflammatory peak occurred (7 hours). Their long-term presence and evolution into monocyte-macrophages (mo-mΦs) up to 7 weeks were monitored histologically using CD68. Distinct inflammatory profiles were further characterized after cell enrichment and fluorescence-activated cell sorting (FACS) distinguishing monocytes/mo-mΦs (CD11b + CD45 hi CD11a hi ) from microglia (CD11b + CD45 lo CD11a lo ). Microglia were the main drivers of the early pro-inflammatory response, with TNFα transcript levels nearly 14-fold higher in microglia than in monocytes 24h post-SE. In contrast, 24h post-SE, infiltrating monocytes transiently displayed an anti-inflammatory and neuroprotective phenotype, being the main source of IL-10, showing ~4-fold higher CD206, and expressing Arg1 absent in microglia. Tracked up to 7 weeks, these cells progressively adopted a microglia-like phenotype, contributed to the microglial scar and, although their expression of pro-inflammatory markers resembled nonactivated microglia, we hypothesize that their persistent presence might fuel the low-grade inflammation typical of chronic epilepsy. Importantly, since infiltrating monocytes initially engage in a transient anti-inflammatory response, strategies aiming to sustain or enhance this protective role in the context of epileptogenesis and epilepsy may open promising avenues for therapeutic intervention.
- Open Access
Extracellular vesicle microRNAs are biomarkers of focal epilepsy but not epilepsy‐related respiratory dysfunction
Objective: This study was undertaken to evaluate the diagnostic value of a set of preselected candidate microRNAs (miRNAs) extracted from plasma‐based extracellular vesicles (EVs) to identify patients with seizure‐related respiratory dysfunction. Methods: A two‐step design was applied. Step 1 entailed selection of the relevant miRNAs based on the combination of a literature review and an exploratory study in epileptic rats with or without interictal respiratory dysfunction. Step 2 involved evaluation of the diagnostic value of this preselected panel of circulating exosomal miRNAs in a case–control study conducted in 25 healthy subjects and 50 patients with drug‐resistant focal epilepsy undergoing video‐electroencephalographic (EEG) monitoring. Based on video‐EEG data, patients were separated into two groups: those with ictal/postictal hypoxemia (PIH; n = 24) and those without (noPIH; n = 26). Blood samples were collected in the interictal period (>24 h after the last seizure). Expression level of each miRNAs in EVs was compared (1) between all patients with epilepsy and controls and (2) between PIH and noPIH. Receiver operating characteristic (ROC) curves were generated, and the area under the curve (AUC) was calculated. Results: Following Step 1, the final set of miRNAs selected for evaluation in the case–control study included 24 miRNAs, with nine selected from published data in patients because of their potential regulatory role in the serotoninergic pathway, brain response to hypoxia, or epilepsy and 15 selected from the preclinical study in epileptic rats. Three miRNAs significantly differed between patients with epilepsy and controls (ROC curve AUC: hsa‐miR‐22‐3p, .74 [95% confidence interval (CI) = .63–.85]; hsa‐miR‐106b‐5p, .69 [95% CI = .57–.82]; and hsa‐miR‐26a‐5p, .72 [95% CI = .58–.85]). Only a trend toward higher expression levels was observed for hsa‐miR‐140‐3p in PIH compared to noPIH (+5%, p = .064). Significance: Whereas three miRNAs were robustly associated with epilepsy, none was significantly associated with seizure‐related respiratory dysfunction. Additional studies are required, including analysis of the expression of plasmatic cell‐free miRNAs, especially the miRNAs associated with interictal respiratory dysfunction in epileptic rats.
Open AccessExtracellular vesicle microRNAs are biomarkers of focal epilepsy but not epilepsy‐related respiratory dysfunction
Objective: This study was undertaken to evaluate the diagnostic value of a set of preselected candidate microRNAs (miRNAs) extracted from plasma‐based extracellular vesicles (EVs) to identify patients with seizure‐related respiratory dysfunction. Methods: A two‐step design was applied. Step 1 entailed selection of the relevant miRNAs based on the combination of a literature review and an exploratory study in epileptic rats with or without interictal respiratory dysfunction. Step 2 involved evaluation of the diagnostic value of this preselected panel of circulating exosomal miRNAs in a case–control study conducted in 25 healthy subjects and 50 patients with drug‐resistant focal epilepsy undergoing video‐electroencephalographic (EEG) monitoring. Based on video‐EEG data, patients were separated into two groups: those with ictal/postictal hypoxemia (PIH; n = 24) and those without (noPIH; n = 26). Blood samples were collected in the interictal period (>24 h after the last seizure). Expression level of each miRNAs in EVs was compared (1) between all patients with epilepsy and controls and (2) between PIH and noPIH. Receiver operating characteristic (ROC) curves were generated, and the area under the curve (AUC) was calculated. Results: Following Step 1, the final set of miRNAs selected for evaluation in the case–control study included 24 miRNAs, with nine selected from published data in patients because of their potential regulatory role in the serotoninergic pathway, brain response to hypoxia, or epilepsy and 15 selected from the preclinical study in epileptic rats. Three miRNAs significantly differed between patients with epilepsy and controls (ROC curve AUC: hsa‐miR‐22‐3p, .74 [95% confidence interval (CI) = .63–.85]; hsa‐miR‐106b‐5p, .69 [95% CI = .57–.82]; and hsa‐miR‐26a‐5p, .72 [95% CI = .58–.85]). Only a trend toward higher expression levels was observed for hsa‐miR‐140‐3p in PIH compared to noPIH (+5%, p = .064). Significance: Whereas three miRNAs were robustly associated with epilepsy, none was significantly associated with seizure‐related respiratory dysfunction. Additional studies are required, including analysis of the expression of plasmatic cell‐free miRNAs, especially the miRNAs associated with interictal respiratory dysfunction in epileptic rats.
- Open Access
Brain Infiltrated Monocyte-Macrophages in a rat model of Temporal Lobe Epilepsy: Revisiting the Pro-Inflammatory Paradigm
Neuroinflammation is central to temporal lobe epilepsy, yet the specific role of myeloid cells remains unclear. In status epilepticus (SE) models, circulating monocytes have been reported to infiltrate the brain, though distinguishing them from microglia remains challenging. Using a rat model, we traced infiltrating monocytes post-SE, to investigate their persistence, phenotypic evolution during epileptogenesis and contribution to neuroinflammation. By tracking phagocyted fluorescent nanoparticles and using CD68 immunohistochemistry, we confirmed that monocytes entered the brain in significant numbers 24 hours post-SE, after the inflammatory peak occurred (7h post-SE). Tracked up to 7 weeks, these cells adopted a microglia-like phenotype, contributed to the microglial scar and sustained low-grade inflammation during the chronic phase of epilepsy solely through their presence, as their expression of pro-inflammatory markers resembled that of non-activated microglia. Importantly, monocytes initially and transiently supported an anti-inflammatory response providing a unique opportunity to modulate neuroinflammation and potentially disrupt epilepsy progression, opening new avenues for therapeutic interventions.
Open AccessBrain Infiltrated Monocyte-Macrophages in a rat model of Temporal Lobe Epilepsy: Revisiting the Pro-Inflammatory Paradigm
Neuroinflammation is central to temporal lobe epilepsy, yet the specific role of myeloid cells remains unclear. In status epilepticus (SE) models, circulating monocytes have been reported to infiltrate the brain, though distinguishing them from microglia remains challenging. Using a rat model, we traced infiltrating monocytes post-SE, to investigate their persistence, phenotypic evolution during epileptogenesis and contribution to neuroinflammation. By tracking phagocyted fluorescent nanoparticles and using CD68 immunohistochemistry, we confirmed that monocytes entered the brain in significant numbers 24 hours post-SE, after the inflammatory peak occurred (7h post-SE). Tracked up to 7 weeks, these cells adopted a microglia-like phenotype, contributed to the microglial scar and sustained low-grade inflammation during the chronic phase of epilepsy solely through their presence, as their expression of pro-inflammatory markers resembled that of non-activated microglia. Importantly, monocytes initially and transiently supported an anti-inflammatory response providing a unique opportunity to modulate neuroinflammation and potentially disrupt epilepsy progression, opening new avenues for therapeutic interventions.
- Open Access
- 19 August 2024
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 21 (1) , 1-16
CB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions
Since its detection in the brain, the cannabinoid receptor type 2 (CB2) has been considered a promising therapeutic target for various neurological and psychiatric disorders. However, precise brain mapping of its expression is still lacking. Using magnetic cell sorting, calibrated RT-qPCR and single-nucleus RNAseq, we show that CB2 is expressed at a low level in all brain regions studied, mainly by few microglial cells, and by neurons in an even lower proportion. Upon lipopolysaccharide stimulation, modeling neuroinflammation in non-sterile conditions, we demonstrate that the inflammatory response is associated with a transient reduction in CB2 mRNA levels in brain tissue, particularly in microglial cells. This result, confirmed in the BV2 microglial cell line, contrasts with the positive correlation observed between CB2 mRNA levels and the inflammatory response upon stimulation by interferon-gamma, modeling neuroinflammation in sterile condition. Discrete brain CB2 expression might thus be up- or down-regulated depending on the inflammatory context.
- 19 August 2024
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 21 (1) , 1-16
Open AccessCB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions
Since its detection in the brain, the cannabinoid receptor type 2 (CB2) has been considered a promising therapeutic target for various neurological and psychiatric disorders. However, precise brain mapping of its expression is still lacking. Using magnetic cell sorting, calibrated RT-qPCR and single-nucleus RNAseq, we show that CB2 is expressed at a low level in all brain regions studied, mainly by few microglial cells, and by neurons in an even lower proportion. Upon lipopolysaccharide stimulation, modeling neuroinflammation in non-sterile conditions, we demonstrate that the inflammatory response is associated with a transient reduction in CB2 mRNA levels in brain tissue, particularly in microglial cells. This result, confirmed in the BV2 microglial cell line, contrasts with the positive correlation observed between CB2 mRNA levels and the inflammatory response upon stimulation by interferon-gamma, modeling neuroinflammation in sterile condition. Discrete brain CB2 expression might thus be up- or down-regulated depending on the inflammatory context.
Serotonin 2C receptor in a rat model of temporal lobe epilepsy: From brainstem expression to pharmacological blockade in relation to ventilatory function
Because of its involvement in breathing control and neuronal excitability, dysregulation of the serotonin (5‐HT) 2C receptor (5‐HT2C) might play a key role in sudden unexpected death in epilepsy. Seizure‐induced respiratory arrest is thus prevented by a 5‐HT2B/C agonist in different seizure model. However, the specific contribution of 5‐HT2C in chronic epilepsy‐related respiratory dysfunction remains unknown. In a rat model of temporal lobe epilepsy (EPI rats), in which we previously reported interictal respiratory dysfunctions and a reduction of brainstem 5‐HT tone, quantitative reverse transcriptase polymerase chain reaction showed overexpression of TPH2 (5‐HT synthesis enzyme), SERT (5‐HT reuptake transporter), and 5‐HT2C transcript levels in the brainstem of EPI rats, and of RNA‐specific adenosine deaminase (ADAR1, ADAR2) involved in the production of 5‐HT2C isoforms. Interictal ventilation was assessed with whole‐body plethysmography before and 2 h after administration of SB242084 (2 mg/kg), a specific antagonist of 5‐HT2C. As expected, SB242084 administration induced a progressive decrease in ventilatory parameters and an alteration of breathing stability in both control and EPI rats. However, the size of the SB242084 effect was lower in EPI rats than in controls. Increased 5‐HT2C gene expression in the brainstem of EPI rats could be part of a compensatory mechanism against epilepsy‐related low 5‐HT tone and expression of 5‐HT2C isoforms for which 5‐HT affinity might be lower.
Serotonin 2C receptor in a rat model of temporal lobe epilepsy: From brainstem expression to pharmacological blockade in relation to ventilatory function
Because of its involvement in breathing control and neuronal excitability, dysregulation of the serotonin (5‐HT) 2C receptor (5‐HT2C) might play a key role in sudden unexpected death in epilepsy. Seizure‐induced respiratory arrest is thus prevented by a 5‐HT2B/C agonist in different seizure model. However, the specific contribution of 5‐HT2C in chronic epilepsy‐related respiratory dysfunction remains unknown. In a rat model of temporal lobe epilepsy (EPI rats), in which we previously reported interictal respiratory dysfunctions and a reduction of brainstem 5‐HT tone, quantitative reverse transcriptase polymerase chain reaction showed overexpression of TPH2 (5‐HT synthesis enzyme), SERT (5‐HT reuptake transporter), and 5‐HT2C transcript levels in the brainstem of EPI rats, and of RNA‐specific adenosine deaminase (ADAR1, ADAR2) involved in the production of 5‐HT2C isoforms. Interictal ventilation was assessed with whole‐body plethysmography before and 2 h after administration of SB242084 (2 mg/kg), a specific antagonist of 5‐HT2C. As expected, SB242084 administration induced a progressive decrease in ventilatory parameters and an alteration of breathing stability in both control and EPI rats. However, the size of the SB242084 effect was lower in EPI rats than in controls. Increased 5‐HT2C gene expression in the brainstem of EPI rats could be part of a compensatory mechanism against epilepsy‐related low 5‐HT tone and expression of 5‐HT2C isoforms for which 5‐HT affinity might be lower.
- Open Access
- 25 January 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (2) , 582-591
Phosphatidylserine enriched with polyunsaturated n‐3 fatty acid supplementation for attention‐deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo‐controlled trial
Background: Attention‐deficit hyperactivity disorder (ADHD) is a frequent comorbidity in children with epilepsy, which management mostly relies on the usual treatments of ADHD, especially methylphenidate. Supplementation with polyunsaturated n‐3 Fatty Acid (PUFA) has been proposed as an alternative therapeutic approach in ADHD without epilepsy but has never been evaluated in epilepsy‐associated ADHD.Methods: A multicenter double blind randomized placebo‐controlled trial evaluating supplementation with PUFA, in eicosapentaenoic‐ and docosahexaenoic‐acid form, conjugated to a phospholipid vector (PS‐Omega3) in children aged >6 and p = 0.33, α = 5%). Results were similar after 24 weeks of treatment and for all other ADHD‐related secondary outcomes, with no difference between placebo and PS‐Omega3.Conclusion: Our study remaining underpowered, no formal conclusion about the effect of Ps‐Omega3 could be drawn. However, our data strongly suggested that the PS‐Omega 3 formulation used in the current study did not improve ADHD symptoms in children with epilepsy.Plain Language Summary: Supplementation with polyunsaturated n‐3 Fatty Acid (PUFA) has been proposed in ADHD but has never been evaluated in patients with both epilepsy and ADHD. To address this issue, we conducted a multicenter double blind randomized placebo‐controlled trial evaluating supplementation with PUFA in children with epilepsy and ADHD. The study was stopped early because of lack of eligible participants, hampering formal conclusion. However, the evolution of the ADHD symptoms at 12 and 24 weeks did not differ between placebo and PUFA supplementation, strongly suggesting that PUFA did not improve ADHD symptoms in children with epilepsy.
- 25 January 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (2) , 582-591
Open AccessPhosphatidylserine enriched with polyunsaturated n‐3 fatty acid supplementation for attention‐deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo‐controlled trial
Background: Attention‐deficit hyperactivity disorder (ADHD) is a frequent comorbidity in children with epilepsy, which management mostly relies on the usual treatments of ADHD, especially methylphenidate. Supplementation with polyunsaturated n‐3 Fatty Acid (PUFA) has been proposed as an alternative therapeutic approach in ADHD without epilepsy but has never been evaluated in epilepsy‐associated ADHD.Methods: A multicenter double blind randomized placebo‐controlled trial evaluating supplementation with PUFA, in eicosapentaenoic‐ and docosahexaenoic‐acid form, conjugated to a phospholipid vector (PS‐Omega3) in children aged >6 and p = 0.33, α = 5%). Results were similar after 24 weeks of treatment and for all other ADHD‐related secondary outcomes, with no difference between placebo and PS‐Omega3.Conclusion: Our study remaining underpowered, no formal conclusion about the effect of Ps‐Omega3 could be drawn. However, our data strongly suggested that the PS‐Omega 3 formulation used in the current study did not improve ADHD symptoms in children with epilepsy.Plain Language Summary: Supplementation with polyunsaturated n‐3 Fatty Acid (PUFA) has been proposed in ADHD but has never been evaluated in patients with both epilepsy and ADHD. To address this issue, we conducted a multicenter double blind randomized placebo‐controlled trial evaluating supplementation with PUFA in children with epilepsy and ADHD. The study was stopped early because of lack of eligible participants, hampering formal conclusion. However, the evolution of the ADHD symptoms at 12 and 24 weeks did not differ between placebo and PUFA supplementation, strongly suggesting that PUFA did not improve ADHD symptoms in children with epilepsy.
Are we there yet? A critical evaluation of sudden and unexpected death in epilepsy models
Although animal models have helped to elaborate meaningful hypotheses about the pathophysiology of sudden and unexpected death in epilepsy (SUDEP), specific prevention strategies are still lacking, potentially reflecting the limitations of these models and the intrinsic difficulties of investigating SUDEP. The interpretation of preclinical data and their translation to diagnostic and therapeutic developments in patients thus require a high level of confidence in their relevance to model the human situation. Preclinical models of SUDEP are heterogeneous and include rodent and nonrodent species. A critical aspect is whether the animals have isolated seizures exclusively induced by a specific trigger, such as models where seizures are elicited by electrical stimulation, pharmacological intervention, or DBA mouse strains, or whether they suffer from epilepsy with spontaneous seizures, with or without spontaneous SUDEP, either of nongenetic epilepsy etiology or from genetically based developmental and epileptic encephalopathies. All these models have advantages and potential disadvantages, but it is important to be aware of these limitations to interpret data appropriately in a translational perspective. The majority of models with spontaneous seizures are of a genetic basis, whereas SUDEP cases with a genetic basis represent only a small proportion of the total number. In almost all models, cardiorespiratory arrest occurs during the course of the seizure, contrary to that in patients observed at the time of death, potentially raising the issue of whether we are studying models of SUDEP or models of periseizure death. However, some of these limitations are impossible to avoid and can in part be dependent on specific features of SUDEP, which may be difficult to model. Several preclinical tools are available to address certain gaps in SUDEP pathophysiology, which can be used to further validate current preclinical models.
Are we there yet? A critical evaluation of sudden and unexpected death in epilepsy models
Although animal models have helped to elaborate meaningful hypotheses about the pathophysiology of sudden and unexpected death in epilepsy (SUDEP), specific prevention strategies are still lacking, potentially reflecting the limitations of these models and the intrinsic difficulties of investigating SUDEP. The interpretation of preclinical data and their translation to diagnostic and therapeutic developments in patients thus require a high level of confidence in their relevance to model the human situation. Preclinical models of SUDEP are heterogeneous and include rodent and nonrodent species. A critical aspect is whether the animals have isolated seizures exclusively induced by a specific trigger, such as models where seizures are elicited by electrical stimulation, pharmacological intervention, or DBA mouse strains, or whether they suffer from epilepsy with spontaneous seizures, with or without spontaneous SUDEP, either of nongenetic epilepsy etiology or from genetically based developmental and epileptic encephalopathies. All these models have advantages and potential disadvantages, but it is important to be aware of these limitations to interpret data appropriately in a translational perspective. The majority of models with spontaneous seizures are of a genetic basis, whereas SUDEP cases with a genetic basis represent only a small proportion of the total number. In almost all models, cardiorespiratory arrest occurs during the course of the seizure, contrary to that in patients observed at the time of death, potentially raising the issue of whether we are studying models of SUDEP or models of periseizure death. However, some of these limitations are impossible to avoid and can in part be dependent on specific features of SUDEP, which may be difficult to model. Several preclinical tools are available to address certain gaps in SUDEP pathophysiology, which can be used to further validate current preclinical models.
- Open Access
Cannabinoid receptor type 2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions
Since its detection in the brain, the cannabinoid receptor type 2 (CB2) has been deemed a promising therapeutic target for various neurological and psychiatric disorders. However, precise brain mapping of CB2 expression is currently lacking. Using magnetic cell sorting, calibrated reverse transcription-quantitative PCR, and single-nucleus RNA-seq, we revealed the low level of CB2 expression in all brain regions examined, mainly by a few microglial cells and by neurons in an even lower proportion. Upon lipopolysaccharide stimulation to simulate non-sterile neuroinflammatory conditions, we demonstrated that the inflammatory response was associated with a transient reduction in CB2 mRNA levels in the brain tissue, particularly in microglia. This result, confirmed in the BV2 microglial cells, contrasts with the positive correlation observed between CB2 mRNA levels and the inflammatory response upon stimulation by interferon-gamma, which models sterile inflammatory conditions. Thus, discrete brain CB2 expression may be upregulated or downregulated depending on the inflammatory context.
Open AccessCannabinoid receptor type 2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions
Since its detection in the brain, the cannabinoid receptor type 2 (CB2) has been deemed a promising therapeutic target for various neurological and psychiatric disorders. However, precise brain mapping of CB2 expression is currently lacking. Using magnetic cell sorting, calibrated reverse transcription-quantitative PCR, and single-nucleus RNA-seq, we revealed the low level of CB2 expression in all brain regions examined, mainly by a few microglial cells and by neurons in an even lower proportion. Upon lipopolysaccharide stimulation to simulate non-sterile neuroinflammatory conditions, we demonstrated that the inflammatory response was associated with a transient reduction in CB2 mRNA levels in the brain tissue, particularly in microglia. This result, confirmed in the BV2 microglial cells, contrasts with the positive correlation observed between CB2 mRNA levels and the inflammatory response upon stimulation by interferon-gamma, which models sterile inflammatory conditions. Thus, discrete brain CB2 expression may be upregulated or downregulated depending on the inflammatory context.
- Top Cited Papers
- 8 May 2023
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 150, 105226
CB2 receptor in the CNS: From immune and neuronal modulation to behavior
- 8 May 2023
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 150, 105226
Top Cited PapersCB2 receptor in the CNS: From immune and neuronal modulation to behavior